Evidence question
How large was the weight effect in a pivotal trial of adults without diabetes?
Result / effect
In SURMOUNT-1, mean weight change was −15.0%, −19.5%, and −20.9% across the three tirzepatide groups, versus −3.1% with placebo.
Evidence chain
Population
Adults with obesity, or overweight with at least one weight-related complication, without diabetes in SURMOUNT-1.
Endpoint
Percentage change in body weight and categorical weight-loss thresholds at 72 weeks.
Evidence level
High. A large phase 3 randomized trial directly measured body-weight outcomes. Applicability depends on population, treatment context, and duration.
What this record does not establish
- SURMOUNT-1 excluded people with diabetes.
- The intervention included dose escalation and lifestyle counseling within a trial protocol.
- Long-term outcomes beyond the trial window require separate evidence.
Linked study records
Sources
- SURMOUNT-1 trial, PubMedRandomized controlled trial
- Zepbound prescribing information, DailyMedRegulatory label